1 Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141-155, doi:10.1146/annurev-med-042909-093756 (2011).
2 Beckman, J. A., Creager, M. A. & Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570-2581, doi:10.1001/jama.287.19.2570 (2002).
3 Lozupone, C. A. et al. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe 14, 329-339, doi:10.1016/j.chom.2013.08.006 (2013).
4 Dillon, S. M. et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 7, 983-994, doi:10.1038/mi.2013.116 (2014).
5 Nowak, P. et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 29, 2409-2418, doi:10.1097/QAD.0000000000000869 (2015).
6 Hartstra, A. V., Bouter, K. E., Backhed, F. & Nieuwdorp, M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 38, 159-165, doi:10.2337/dc14-0769 (2015).
7 Cani, P. D., Osto, M., Geurts, L. & Everard, A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 3, 279-288, doi:10.4161/gmic.19625 (2012).
8 Manco, M., Putignani, L. & Bottazzo, G. F. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr. Rev. 31, 817-844, doi:10.1210/er.2009-0030 (2010).
9 Kasselman, L. J., Vernice, N. A., DeLeon, J. & Reiss, A. B. The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity. Atherosclerosis 271, 203-213, doi:10.1016/j.atherosclerosis.2018.02.036 (2018).
10 Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371, doi:10.1038/nm1511 (2006).
11 Creely, S. J. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292, E740-747, doi:10.1152/ajpendo.00302.2006 (2007).
12 Pedersen, K. K. et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J. Acquir. Immune Defic. Syndr. 64, 425-433, doi:10.1097/QAI.0b013e31829f919d (2013).
13 Troseid, M. et al. Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res. Hum. Retroviruses 30, 514-522, doi:10.1089/AID.2013.0280 (2014).
14 Tulkens, J. et al. Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction. Gut 69, 191-193, doi:10.1136/gutjnl-2018-317726 (2020).
15 Yanez-Mo, M. et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4, 27066, doi:10.3402/jev.v4.27066 (2015).
16 Raab-Traub, N. & Dittmer, D. P. Viral effects on the content and function of extracellular vesicles. Nat Rev Microbiol 15, 559-572, doi:10.1038/nrmicro.2017.60 (2017).
17 Kaparakis-Liaskos, M. & Ferrero, R. L. Immune modulation by bacterial outer membrane vesicles. Nat. Rev. Immunol. 15, 375-387, doi:10.1038/nri3837 (2015).
18 Buzas, E. I., Gyorgy, B., Nagy, G., Falus, A. & Gay, S. Emerging role of extracellular vesicles in inflammatory diseases. Nat. Rev. Rheumatol. 10, 356-364, doi:10.1038/nrrheum.2014.19 (2014).
19 Jansen, F., Nickenig, G. & Werner, N. Extracellular Vesicles in Cardiovascular Disease: Potential Applications in Diagnosis, Prognosis, and Epidemiology. Circ. Res. 120, 1649-1657, doi:10.1161/CIRCRESAHA.117.310752 (2017).
20 Chong, S. Y. et al. Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers. Int. J. Mol. Sci. 20, doi:10.3390/ijms20133272 (2019).
21 Sekirov, I., Russell, S. L., Antunes, L. C. & Finlay, B. B. Gut microbiota in health and disease. Physiol. Rev. 90, 859-904, doi:10.1152/physrev.00045.2009 (2010).
22 Kamada, N., Seo, S. U., Chen, G. Y. & Nunez, G. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13, 321-335, doi:10.1038/nri3430 (2013).
23 Hoel, H. et al. Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction. Sci. Rep. 8, 6725, doi:10.1038/s41598-018-25168-3 (2018).
24 de Menezes-Neto, A. et al. Size-exclusion chromatography as a stand-alone methodology identifies novel markers in mass spectrometry analyses of plasma-derived vesicles from healthy individuals. J. Extracell. Vesicles 4, 27378, doi:10.3402/jev.v4.27378 (2015).
25 Gamez-Valero, A. et al. Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesicles' characteristics compared to precipitating agents. Sci. Rep. 6, 33641, doi:10.1038/srep33641 (2016).
26 Boing, A. N. et al. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J. Extracell. Vesicles 3, doi:10.3402/jev.v3.23430 (2014).
27 Kreimer, S. & Ivanov, A. R. Rapid Isolation of Extracellular Vesicles from Blood Plasma with Size-Exclusion Chromatography Followed by Mass Spectrometry-Based Proteomic Profiling. Methods Mol. Biol. 1660, 295-302, doi:10.1007/978-1-4939-7253-1_24 (2017).
28 Karimi, N. et al. Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins. Cell. Mol. Life Sci. 75, 2873-2886, doi:10.1007/s00018-018-2773-4 (2018).
29 Brennan, K. et al. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci. Rep. 10, 1039, doi:10.1038/s41598-020-57497-7 (2020).
30 Onodi, Z. et al. Isolation of High-Purity Extracellular Vesicles by the Combination of Iodixanol Density Gradient Ultracentrifugation and Bind-Elute Chromatography From Blood Plasma. Front. Physiol. 9, 1479, doi:10.3389/fphys.2018.01479 (2018).
31 Palviainen, M. et al. Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo-Implications for biomarker discovery. PLoS One 15, e0236439, doi:10.1371/journal.pone.0236439 (2020).
32 Buzas, E. I., Toth, E. A., Sodar, B. W. & Szabo-Taylor, K. E. Molecular interactions at the surface of extracellular vesicles. Semin. Immunopathol. 40, 453-464, doi:10.1007/s00281-018-0682-0 (2018).
33 Lee, J. H. et al. HIV-Nef and ADAM17-Containing Plasma Extracellular Vesicles Induce and Correlate with Immune Pathogenesis in Chronic HIV Infection. EBioMedicine 6, 103-113, doi:10.1016/j.ebiom.2016.03.004 (2016).
34 Hubert, A. et al. Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+ Patients: Correlations With Known Markers of Disease Progression. J. Acquir. Immune Defic. Syndr. 70, 219-227, doi:10.1097/QAI.0000000000000756 (2015).
35 Chettimada, S. et al. Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy. Sci. Rep. 8, 7227, doi:10.1038/s41598-018-25515-4 (2018).
36 Diamant, M. et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 106, 2442-2447, doi:10.1161/01.cir.0000036596.59665.c6 (2002).
37 Freeman, D. W. et al. Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes. Diabetes 67, 2377-2388, doi:10.2337/db17-1308 (2018).
38 Levels, J. H., Abraham, P. R., van den Ende, A. & van Deventer, S. J. Distribution and kinetics of lipoprotein-bound endotoxin. Infect. Immun. 69, 2821-2828, doi:10.1128/IAI.69.5.2821-2828.2001 (2001).
39 Parker, T. S. et al. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 63, 253-258 (1995).
40 Gelpi, M. et al. Impact of Hiv-Related Gut Microbiota Alterations on Metabolic Comorbidities. Clin. Infect. Dis., doi:10.1093/cid/ciz1235 (2020).
41 Choi, Y. et al. Gut microbe-derived extracellular vesicles induce insulin resistance, thereby impairing glucose metabolism in skeletal muscle. Sci. Rep. 5, 15878, doi:10.1038/srep15878 (2015).
42 Borges, A. H. et al. Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. J. Infect. Dis. 214, 408-416, doi:10.1093/infdis/jiw173 (2016).
43 Borges, A. H. et al. Factors Associated With Plasma IL-6 Levels During HIV Infection. J. Infect. Dis. 212, 585-595, doi:10.1093/infdis/jiv123 (2015).
44 Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843, doi:10.1056/NEJM200003233421202 (2000).
45 Hoel, H. et al. Soluble Markers of Interleukin 1 Activation as Predictors of First-Time Myocardial Infarction in HIV-Infected Individuals. J. Infect. Dis. 221, 506-509, doi:10.1093/infdis/jiz253 (2020).
46 Aday, A. W. & Ridker, P. M. Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. Front Cardiovasc Med 5, 62, doi:10.3389/fcvm.2018.00062 (2018).
47 Sundar, I. K., Li, D. & Rahman, I. Small RNA-sequence analysis of plasma-derived extracellular vesicle miRNAs in smokers and patients with chronic obstructive pulmonary disease as circulating biomarkers. J. Extracell. Vesicles 8, 1684816, doi:10.1080/20013078.2019.1684816 (2019).
48 Sanjurjo, L., Aran, G., Roher, N., Valledor, A. F. & Sarrias, M. R. AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease. J. Leukoc. Biol. 98, 173-184, doi:10.1189/jlb.3RU0215-074R (2015).
49 Gleissner, C. A. et al. Galectin-3 binding protein plasma levels are associated with long-term mortality in coronary artery disease independent of plaque morphology. Atherosclerosis 251, 94-100, doi:10.1016/j.atherosclerosis.2016.06.002 (2016).
50 Hove-Skovsgaard, M. et al. HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation. BMC Infect Dis 17, 234, doi:10.1186/s12879-017-2334-8 (2017).
51 Puhka, M. et al. KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine. Eur. J. Pharm. Sci. 98, 30-39, doi:10.1016/j.ejps.2016.10.021 (2017).
52 Vestad, B. et al. Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. J. Extracell. Vesicles 6, 1344087, doi:10.1080/20013078.2017.1344087 (2017).
53 Consortium, E.-T. et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods 14, 228-232, doi:10.1038/nmeth.4185 (2017).